price close busi april
medic devic heart valv therapi includ
tissu valv mechan valv repair product
biomed devic servic
buy ahead tavr acceler mitral catalyst
bottom line relat tavr growth us ou expect
repres low water mark perhap go far estim
check indic low-risk approv could come earli late
estim acceler tavr growth market ew lost modest
share europ maintain possibl even gain tad tavr
share us think under-appreci increment catalyst ew
tavr growth propos ncd revis think posit tailwind
overal tavr growth could augment ew posit us market given focu
center qualiti outcom specif ppm rate recal lr data metric
outstand absolut basi rel mdt lr data importantli
come tavr us ww modestli miss us/consensu
manag reiter confid achiev tavr global growth
portend signific tavr acceler level think achiev given
palpabl excit around tavr gener sapien specif discern
physician subsequ
furthermor firm demonstr robust oper margin leverag
notwithstand in-lin revenu result owe part conserv guidanc
view oper effici also expens defer said tavr inde
acceler guidanc research impli think model deliv
leverag reflect even upwardli revis ep guidanc
sum would accumul ew large-cap portfolio primarili owe tavr
growth acceler long-term still rel under-penetr ew reiter
call tavr market vs forward earn leverag
portend ep current consensu mitral/tricuspid
opportun could hit earlier impact expect name
pascal alreadi proven case reiter buy year-
tavr busi highlight ew tavr perform didnt deliv upsid
estim underli growth result larg line firm
expect guidanc expect tavr sale ramp sequenti
level acceler heel low-risk approv continu believ
could come earli ew continu guid us ew tavr
busi grew rel line market low double-digit ou ew
growth remain slightli low-double-digit market growth rate europ
expect recent initi launch ultra centera region support
ew ou perform platform provid limit impact firm
priorit implement control initi roll-out also view japan anoth
bright spot firm continu see strong although small rel volum
basi growth region look ahead manag reiter tavr
sale guidanc continu expect ew underli tavr global growth rang
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
tavr busi highlight continu expect tavr market tailwind
becom pronounc throughout highlight low-risk approv
point think overal growth ew market could acceler
lotu edg approv comment yesterday announc fda approv
bsx lotu edg tavr platform manag note current tavr
guidanc incorpor assumpt mid-year lotu approv well
portico approv year end bsx on-going launch europ upcom
plan launch platform us next week line ew
forecast assumpt anticip captur volum share
lotu sentinel bundl augment bsx competit proposit
certain degre think larger tavr center scale stock
multipl tavr platform key initi lotu site adopt expect
lotu join rank evolut addit altern platform
option furthermor heel stellar low-risk data show
extrem low stroke rate think nyse rate
lose boston scientif nyse buy embol
protect proposit ew
propos ncd continu view potenti market expand
commentari yesterday call reinforc posit outlook current
propos ncd coverag stipul posit tavr market
growth behind expans addit geographi increas patient
access technolog recent state heel propos
decis see note believ myriad propos updat ncd
portend follow larger pool tavr center us potenti abl
meet qualif becom tavr center importantli
stronger commit requir part new exist tavr center
build larger volum tavr patient think could augment tavr
outcom overal vis-a-vi experi compani view propos
memo better reflect current practic environ need patient
transit focu procedur volum patient metric determin
hospit viabil tavr center repres win tavr field
whole expect ncd final bar major
updat think littl chang signific long-term market
forthcom tavr market evolut larg volum center chief
growth driver view ew late seen higher growth
newer/smal center think signific market expans heel low-
risk approv ultim stem current high-volum center
propos ncd updat low risk abil remov risk stratif view
signific potenti patient screen improv materi drive
enhanc patient throughput high volum center ultim support
ramp market growth think could sustain least
longer
tmtt busi outlook ew record total tmtt sale
signific sequenti step total tmtt sale recent
ce mark approv pascal ahead firm approv project
drive growth current cardioband suppli constraint eas
throughout year base initi strong result manag expect pascal
chief contributor tmtt sale notwithstand ad risk
number stem on-going pascal litig pascal initi launch
sale trend provid manag increas confid achiev
biomed devic servic
firm total sale target longer term manag continu
expect global tmtt market reach least level think
outlook top-lin guidanc reiter manag reiter
expect full-year sale rang sale
expect margin back-end load sale ramp sequenti
level benefit back half year low-risk data/label
expans think earlier-than-anticip fda low-risk approv current
project year-end think indic expans could come soon
could drive upsid current estim busi segment
compani reiter expect deliv total tavr thvt sale
rang total surgic heart revenu rang
critic base strong trend
incorpor recent close casm acquisit total busi segment
sale expect rang vs previous
casm expect fairli minim impact total sale
manag continu project total tmtt revenu ramp
sequenti throughout year fuel pascal europ aid
updat guidanc manag continu expect signific y/i
gross margin expans gm anticip rang vs
suppli chain enhanc coupl improv mix name
higher tavr volum off-set current/upcom product
launch fx expect provid posit gm contribut well firm
expect continu invest heavili structur heart growth vector
 expens percentag sale reiter rang
tavr remain ew largest invest dollar standpoint
 expens ultim like repres high-wat mark
firm sale manag view sg project rang
flat y/i adjust oper margin project rang
bottom line manag increas adjust ep expect
reflect perform well includ casm acquisit
firm project pro-forma ep rang vs
previous firm anticip gener rang
guidanc manag anticip total sale rang
adjust ep expect rang factor
full-year guidanc ew expect sequenti ramp sale throughout
figur edward result vs cg estim consensu project
biomed devic servic
deriv price target appli price-to-earnings
pro forma ep estim
biomed devic servic
p/e/g valuat financi metric use current mean large-cap medic devic price-to-earnings multipl ex outlier med-tech comp group ep compound-annual-growth-rate forward impli forma ep growth p/e/g multipl price-to-earnings multipl forma mo patient year year year american age aortic age sever sever symptomat etiolog s/ ssa primari etiolog pe patient yr severe/symptomat ssa pe patient yr yr severe/symptomat ssa pe patient consid high risk surgeri consid intermedi risk surgeri consid risk surgeri consid high risk surgeri consid intermedi risk surgeri consid risk surgeri tavr market opportun tavr market opportun aortic stenosi elderli diseas preval number candid transcathet aortic valv replac meta-analysi model studi canaccord genuiti estim -conserv assum preval old age euroheart survey primari reason age lv canccord genuiti primari research ew compani report investor day assum ou market europe/japan us figur tavi ww market share
biomed devic servic
edward lifesci averag implant center total unit total ew ww tavi revenu ex growth averag total unit total ww tavi revenu growth averag total unit total ww tavi revenu growth player ww tavi revenu ww implant patient popul player tavi ww revenu market lifesci implant averag implant total unit asp ew us revenu averag total unit asp total us revenu averag total unit asp us revenu player us revenu us implant address patient penetr us tavr market figur tavi eu/row market share
biomed devic servic
detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact inform appear front page report
biomed devic servic
million except per share revenu gross oper expens incom pre-tax incom tax interest exp eitf add-back net incom share ep forma ex ia margin analysi gross margin pro sale sale y/i revenu growth growth growth incom pro forma incom forma ex-one-tim ia figur revenu model
biomed devic servic
heart valv aortic/mitr replacement/repairaort tavi sapien product royalti us total tavi mitral/trucuspid total tmvr/re total transcathet valv therapi surgic heart valv therapytissu repair surgic heart valv cardiac surgeri cardiac surgeri total surgic hv cs surgic valv consign total surgic hv/c revenu critic hemodynam pressur critic vascular vascular total critic vascular revenu pro forma total revenu figur revenu model part
biomed devic servic
